ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Multimodality treatment and survival in primary cardiac malignancies: evidence from competing-risk and machine learning analyses.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary cardiac malignancies are rare and highly aggressive, with limited clinical evidence to guide optimal treatment. This study evaluated the association between multimodal treatments and survival outcomes under competing-risk conditions.
methodsA retrospective cohort analysis was conducted using SEER-18 data (2000-2018) to identify patients with cardiac malignancies. Overall survival and cause-specific mortality were assessed using Kaplan-Meier and Fine-Gray competing-risk models. Multimodal treatment effects were examined using adjusted regression analyses. Prognostic performance was further evaluated using machine learning methods, including random survival forests and survival trees, with discrimination, calibration, and Brier scores assessed in a validation cohort.
resultsAmong 416 patients, angiosarcoma predominated, most had regional/distant disease, surgery and chemotherapy were common, and over 80% experienced either primary cardiac malignancy-specific mortality or other-cause mortality. Chemotherapy plus surgery was associated with lower primary cardiac malignancy-specific mortality (AHR: 0.72; 95% CI 0.54-0.95) and other-cause mortality (AHR: 0.58; 95% CI 0.36-0.93). Surgery with radiotherapy was not significantly associated with primary cardiac malignancy-specific survival but with lower other-cause mortality (AHR: 0.44; 95% CI 0.22-0.87). Compared with surgery alone, multimodal combinations were not significantly associated with primary cardiac malignancy-specific mortality; however, surgery with chemotherapy (AHR: 0.54), surgery with radiation (AHR: 0.29), and triple therapy (AHR: 0.34) were linked to lower other-cause mortality. Regression tree revealed age- and stage-specific heterogeneity, with greater survival likelihood among patients ≤ 65 years with regional/distant disease who underwent surgery.
conclusionSurgery, particularly when combined with chemotherapy, was associated with improved outcomes. Benefits varied by age and stage, underscoring the need for individualized multimodal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.